These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8610631)

  • 1. The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).
    Flaherty LE; Liu PY; Mitchell MS; Fletcher WS; Walker MJ; Goodwin JW; Stephens RL; Sondak VK
    Am J Clin Oncol; 1996 Apr; 19(2):108-13. PubMed ID: 8610631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial.
    Margolin KA; Liu PY; Unger JM; Fletcher WS; Flaherty LE; Urba WJ; Hersh EM; Hutchins LE; Sosman JA; Smith JW; Weiss GR; Sondak VK
    J Cancer Res Clin Oncol; 1999; 125(5):292-6. PubMed ID: 10359134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.
    Chiarion Sileni V; Nortilli R; Aversa SM; Paccagnella A; Medici M; Corti L; Favaretto AG; Cetto GL; Monfardini S
    Melanoma Res; 2001 Apr; 11(2):189-96. PubMed ID: 11333130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
    Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
    J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
    Margolin KA; Liu PY; Flaherty LE; Sosman JA; Walker MJ; Smith JW; Fletcher WS; Weiss GR; Unger JM; Sondak VK
    J Clin Oncol; 1998 Feb; 16(2):664-9. PubMed ID: 9469356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.
    Buzaid AC; Murren JR; Durivage HJ
    Cancer; 1991 Sep; 68(6):1238-41. PubMed ID: 1873775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
    Sertoli MR; Queirolo P; Bajetta E; Del Vecchio M; Comella G; Barduagni L; Bernengo MG; Vecchio S; Criscuolo D; Bufalino R; Morabito A; Cascinelli N
    Melanoma Res; 1999 Oct; 9(5):503-9. PubMed ID: 10596917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
    Tan EH; Ang PT
    Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
    Chapman PB; Einhorn LH; Meyers ML; Saxman S; Destro AN; Panageas KS; Begg CB; Agarwala SS; Schuchter LM; Ernstoff MS; Houghton AN; Kirkwood JM
    J Clin Oncol; 1999 Sep; 17(9):2745-51. PubMed ID: 10561349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
    Fierro MT; Bertero M; Novelli M; Appino A; Doveil GC; Colonna S; Bernengo MG
    Melanoma Res; 1993 Apr; 3(2):127-31. PubMed ID: 8518551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up.
    Lattanzi SC; Tosteson T; Chertoff J; Maurer LH; O'Donnell J; LeMarbre PJ; Mott L; DelPrete SA; Forcier RJ; Ernstoff MS
    Melanoma Res; 1995 Oct; 5(5):365-9. PubMed ID: 8541728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
    Atkins MB; O'Boyle KR; Sosman JA; Weiss GR; Margolin KA; Ernest ML; Kappler K; Mier JW; Sparano JA; Fisher RI
    J Clin Oncol; 1994 Aug; 12(8):1553-60. PubMed ID: 8040667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
    Richard MA; Grob JJ; Zarrour H; Bassères N; Bizzari JP; Gérard B; Bonerandi JJ
    Melanoma Res; 1998 Apr; 8(2):170-4. PubMed ID: 9610872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
    Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
    Ann Plast Surg; 1992 Jan; 28(1):65-9. PubMed ID: 1642409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
    Papadopoulos NE; Bedikian A; Ring S; Kim KB; Hwu WJ; Gerber DL; Homsi J; Hwu P
    Am J Clin Oncol; 2009 Oct; 32(5):509-14. PubMed ID: 19506454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin.
    Nathanson L; Meelu MA; Losada R
    Cancer; 1994 Jan; 73(1):98-102. PubMed ID: 8275444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.